Omicron Variant of SARS-CoV-2: An Indian Perspective of Vaccination and Management
- PMID: 36680006
- PMCID: PMC9860853
- DOI: 10.3390/vaccines11010160
Omicron Variant of SARS-CoV-2: An Indian Perspective of Vaccination and Management
Abstract
Omicron variants have highly influenced the entire globe. It has a high rate of transmissibility, which makes its management tedious. There are various subtypes of omicron, namely BA.1, BA.2, BA.3, BA.4, and BA.5. Currently, one omicron subvariant BF.7 is also immersed in some parts of India. Further studies are required for a better understanding of the new immersing SARS-CoV-2 subvariant of the omicron. They differ in the mutation of the spike proteins, which alters their attachment to the host receptor and hence modifies their virulence and adaptability. Delta variants have a great disastrous influence on the entire world, especially in India. While overcoming it, another mutant catches the pace. The Indian population is highly affected by omicron variants. It alters the entire management and diagnosis system against COVID-19. It demanded forcemeat in the health care system, both qualitatively and quantitively, to cope with the omicron wave. The alteration in spike protein, which is the major target of vaccines, leads to varied immunization against the subvariants. The efficacy of vaccines against the new variant was questioned. Every vaccine had a different shielding effect on the new variant. The hesitancy of vaccination was a prevalent factor in India that might have contributed to its outbreak. The prevalence of omicron, monkeypox, and tomato flu shared some similarities and distinct features when compared to their influence on the Indian population. This review emphasizes the changes omicron brings with it and how the Indian health care system outrage this dangerous variant.
Keywords: India; diagnosis; hesitancy; monkeypox; omicron; tomato flu; vaccination.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



Similar articles
-
Omicron variant evolution on vaccines and monoclonal antibodies.Inflammopharmacology. 2023 Aug;31(4):1779-1788. doi: 10.1007/s10787-023-01253-6. Epub 2023 May 19. Inflammopharmacology. 2023. PMID: 37204696 Free PMC article. Review.
-
Risk evaluation and mitigation strategies for newly detected SARS-CoV-2 Omicron BF.7 subvariant: A brief report.Health Sci Rep. 2023 Mar 2;6(3):e1127. doi: 10.1002/hsr2.1127. eCollection 2023 Mar. Health Sci Rep. 2023. PMID: 36875932 Free PMC article.
-
Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England.JAMA Netw Open. 2022 Oct 3;5(10):e2238354. doi: 10.1001/jamanetworkopen.2022.38354. JAMA Netw Open. 2022. PMID: 36282501 Free PMC article.
-
Boosting with variant-matched adenovirus-based vaccines promotes neutralizing antibody responses against SARS-CoV-2 Omicron sublineages in mice.Int J Antimicrob Agents. 2024 Mar;63(3):107082. doi: 10.1016/j.ijantimicag.2023.107082. Epub 2023 Dec 30. Int J Antimicrob Agents. 2024. PMID: 38163552
-
As the SARS-CoV-2 virus evolves, should Omicron subvariant BA.2 be subjected to quarantine, or should we learn to live with it?Front Public Health. 2022 Nov 24;10:1039123. doi: 10.3389/fpubh.2022.1039123. eCollection 2022. Front Public Health. 2022. PMID: 36504951 Free PMC article. Review.
Cited by
-
A SARS-CoV-2: Companion Animal Transmission and Variants Classification.Pathogens. 2023 May 29;12(6):775. doi: 10.3390/pathogens12060775. Pathogens. 2023. PMID: 37375465 Free PMC article. Review.
-
Early 2022 breakthrough infection sera from India target the conserved cryptic class 5 epitope to counteract immune escape by SARS-CoV-2 variants.J Virol. 2025 Apr 15;99(4):e0005125. doi: 10.1128/jvi.00051-25. Epub 2025 Mar 26. J Virol. 2025. PMID: 40135898 Free PMC article.
-
Therapeutic Potential of Neutralizing Monoclonal Antibodies (nMAbs) against SARS-CoV-2 Omicron Variant.Curr Pharm Des. 2025;31(10):753-773. doi: 10.2174/0113816128334441241108050528. Curr Pharm Des. 2025. PMID: 39543801 Review.
-
An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines.Biomolecules. 2023 Oct 24;13(11):1565. doi: 10.3390/biom13111565. Biomolecules. 2023. PMID: 38002247 Free PMC article. Review.
-
Variants of SARS-CoV-2: Influences on the Vaccines' Effectiveness and Possible Strategies to Overcome Their Consequences.Medicina (Kaunas). 2023 Mar 5;59(3):507. doi: 10.3390/medicina59030507. Medicina (Kaunas). 2023. PMID: 36984508 Free PMC article. Review.
References
-
- Fonseca P.L.C., Moreira F.R.R., de Souza R.M., Guimarães N.R., Carvalho N.O., Adelino T.E.R., Alves H.J., Alvim L.B., Candido D.S., Coelho H.P., et al. Tracking the Turnover of SARS-CoV-2 VOCs Gamma to Delta in a Brazilian State (Minas Gerais) with a High-Vaccination Status. Virus Evol. 2022;8:veac064. doi: 10.1093/ve/veac064. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous